Shopping Cart
- Remove All
- Your shopping cart is currently empty
ACT-1016-0707 is a potent, selective, and insurmountable lysophosphatidic acid receptor 1 (LPA1) antagonist,ACT-1016-0707 demonstrates pronounced antifibrotic and anti-inflammatory activities in experimental models. ACT-1016-0707 has been studied extensively in vitro and in vivo lung fibrosis models, where it reduces pathological fibrotic progression, thereby representing a candidate compound for research into fibrotic lung diseases.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $78 | In Stock | |
5 mg | $196 | In Stock | |
10 mg | $295 | In Stock | |
25 mg | $519 | In Stock | |
50 mg | $787 | In Stock | |
100 mg | $1,070 | In Stock | |
200 mg | $1,430 | In Stock |
Description | ACT-1016-0707 is a potent, selective, and insurmountable lysophosphatidic acid receptor 1 (LPA1) antagonist,ACT-1016-0707 demonstrates pronounced antifibrotic and anti-inflammatory activities in experimental models. ACT-1016-0707 has been studied extensively in vitro and in vivo lung fibrosis models, where it reduces pathological fibrotic progression, thereby representing a candidate compound for research into fibrotic lung diseases. |
Synonyms | LPA1 receptor antagonist 2 |
Molecular Weight | 438.93 |
Formula | C19H23ClN4O4S |
Cas No. | 2569467-78-1 |
Smiles | C(NC=1C(OC)=CC(Cl)=NC1)(=O)C2(CN(S(N)(=O)=O)C2)C3=C(C(C)C)C=CC=C3 |
Color | White |
Appearance | Solid |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (182.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.